All In Biotech

Drug Trial Radar · NCT06189391

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

An Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-1045 (CN201) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 16, 2021

Primary completion

Sep 30, 2028

Study completion Mar 30, 2029

Sponsor

Lead sponsor
MSD R&D (China) Co., Ltd.Merck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment. MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about: * The safety of MK-1045 and how well people tolerate it. * The highest dose of MK-1045 that is well tolerated. * How well MK-1045 works to treat relapsed or refractory B-NHL.

Conditions

  • Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

  • MK-1045Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience a Dose-limiting Toxicity (DLT)Time frame: Up to ~28 Days
  2. Number of Participants who Experience an Adverse Event (AE)Time frame: Up to ~15 months
  3. Number of Participants who Experience a Serious Adverse Events (SAE)Time frame: Up to ~15 months
  4. Number of Participants who Experience a Drug-related Adverse Event (DRAE)Time frame: Up to ~15 months
  5. Number of Participants who Experience an AE of Grade 3 or higherTime frame: Up to ~15 months
  6. Number of Participants who Experience an AE for Each Severity Grade from 1-5Time frame: Up to ~15 months
  7. Number of Participants who Experience a SAE or Serious Drug-related AETime frame: Up to ~15 months
  8. Number of Participants who Experience a Dose Modification Due to an AE or DRAETime frame: Up to ~15 months
  9. Number of Participants who Withdraw from the Study due to an AE or DRAETime frame: Up to ~15 months
  10. Number of Participants who Died due to an AE or DRAETime frame: Up to ~15 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Fifth Medical Center of PLA General Hospital ( Site 0005)

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer hospital ( Site 0001)

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University ( Site 0011)

    Xiameng, Fujian, China · Recruiting

  • Sun Yat-Sen University Cancer Center ( Site 0003)

    Guangzhou, Guangdong, China · Recruiting

  • The Fourth Hospital of Hebei Medical University. ( Site 0004)

    Shijiazhuang, Hebei, China · Recruiting

  • Henan Cancer Hospital ( Site 0009)

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University ( Site 0006)

    Zhengzhou, Henan, China · Recruiting

  • Jiangxi Cancer Hospital ( Site 0007)

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital Of Jilin University ( Site 0014)

    Changchun, Jilin, China · Recruiting

  • Shandong Cancer Hospital ( Site 0008)

    Jinan, Shandong, China · Active not recruiting

  • Fudan University Shanghai Cancer Center ( Site 0012)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital,Fudan University ( Site 0013)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai East Hospital ( Site 0002)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Cancer Hospital. ( Site 0018)

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital ( Site 0010)

    Tianjinc, Tianjin Municipality, China · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.